SCHEMBL8715412

SCHEMBL8715412

O=P(O)(O)C1(P(=O)(O)O)CCCC1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594470 0.97 TSHR (0.55) TSHRCYP2C19GAA
Methane SCHEMBL11431040 0.94 TSHR (0.52) TSHRCYP2C19
SCHEMBL9538717 0.93 TSHR (0.43) TSHRCYP2C19GAA
SCHEMBL28631634 0.74 TSHR (0.40) TSHRCYP2C19
SCHEMBL6688088 0.73 TSHR (0.50) TSHRCYP2C19
SCHEMBL11420149 0.69 TSHR (0.46) TSHRCYP2C19
SCHEMBL5918873 0.69 TSHR (0.94) TSHRCYP2C19
SCHEMBL3291898 0.69 TSHR (0.52) TSHRCYP2C19
SCHEMBL27792298 0.67 TSHR (0.50) TSHRCYP2C19
SCHEMBL5918886 0.67 TSHR (1.00) TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109195641-B Improved implant treatment with phosphonic acid compounds 纳米桥接分子股份公司 2021-07-27 CN claimed
EP-3413934-A1 IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS Nano Bridging Molecules SA (CH) 2018-12-19 EP claimed
WO-2017137623-A1 IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS NANO BRIDGING MOLECULES SA (CH) 2017-08-17 WO claimed
EP-0304961-A2 Novel diphosphonates and use thereof in pharmaceutical compositions THE PROCTER & GAMBLE COMPANY (US) 1989-03-01 EP claimed
EP-0189662-A1 Novel diphosphonates and use thereof in pharmaceutical compositions THE PROCTER & GAMBLE COMPANY (US) 1986-08-06 EP claimed
EP-3413934-A1 IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS Nano Bridging Molecules SA (CH) 2018-12-19 EP disclosed
WO-2017137623-A1 IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS NANO BRIDGING MOLECULES SA (CH) 2017-08-17 WO disclosed
US-5763611-A TREATING OSTEOPOROSIS, RHEUMATOID ARTHRITIS THE PROCTER & GAMBLE COMPANY (US) 1998-06-09 US disclosed
EP-0642520-A1 THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS (US) 1995-03-15 EP disclosed
US-5393746-A Bone disorders P&G PHARMACEUTICALS, INC. (US) 1995-02-28 US disclosed
WO-1993024497-A1 THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
US-5137880-A Treatment for osteoporosis, pagents disease arthritis NORWICH EATON PHARMACEUTICALS, INC. (US) 1992-08-11 US disclosed
EP-0273514-B1 NOVEL BICYCLIC DIPHOSPHONATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS Norwich Eaton Pharmaceuticals, Inc. (US) 1990-12-12 EP disclosed
US-4939131-A Certain cycloalkane-1,1-diphosphonic acids and derivatives thereof having the ability to treat diseases associated with abnormal calcium and phosphate metabolism THE PROCTER & GAMBLE COMPANY (US) 1990-07-03 US disclosed
US-4868164-A OSTEOPOROSIS, ARTHRITIS NORWICH EATON PHARMACEUTICALS, INC. (US) 1989-09-19 US disclosed
EP-0304962-A2 Novel diphosphonates and use thereof in pharmaceutical compositions THE PROCTER & GAMBLE COMPANY (US) 1989-03-01 EP disclosed
EP-0304961-A2 Novel diphosphonates and use thereof in pharmaceutical compositions THE PROCTER & GAMBLE COMPANY (US) 1989-03-01 EP disclosed
EP-0273514-A1 Novel bicyclic diphosphonate compounds and pharmaceutical compositions Norwich Eaton Pharmaceuticals, Inc. (US) 1988-07-06 EP disclosed
US-4687768-A OSTEOPOROSIS, ARTHRITIS THE PROCTER & GAMBLE COMPANY (US) 1987-08-18 US disclosed
EP-0189662-A1 Novel diphosphonates and use thereof in pharmaceutical compositions THE PROCTER & GAMBLE COMPANY (US) 1986-08-06 EP disclosed